Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03947619 · ClinicalTrials.gov registry record · NA
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
A NA study of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall, sponsored by Abiomed.
- Active
- Registry status
- NA
- Development phase
- 527
- Enrollment target
- 20
- Study locations
NCT03947619: Active NA study of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall, sponsored by Abiomed.
NCT03947619 is a NA study of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall that is active but no longer recruiting, run by Abiomed. The registered enrollment target is 527 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03947619, a NA study of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall, is active but no longer recruiting, sponsored by Abiomed.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 527 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
Primary Outcome
Infarct size normalized to the left ventricular mass, evaluated using Cardiac Magnetic Resonance (CMR) imaging
Conditions Studied
Interventions
- DEVICE Impella CP® placement prior to reperfusion with Primary PCI
Study Locations (20)
Florida
- BayCare Cardiology - Morton Plant Hospital - Clearwater
- Baptist Health Research Institute - Jacksonville
- Tallahasse Research Institute - Tallahassee
- AdventHealth - Tampa - Tampa
Illinois
- North Shore University Health System - Evanston
- Midwest Cardiovascular Institute - Naperville
- OSF Saint Francis - Peoria
- Southern Illinois University School of Medicine - Springfield
Arizona
- HonorHealth Research Institute - Scottsdale
- The University of Arizona - Tucson
California
- Emanate Health Intercommunity Hospital / Valley Clinical Trials, Inc. - Covina
- Riverside Community Hospital - Riverside
Georgia
- Northside Hospital - Atlanta
- Wellstar/Kennestone Hospital - Marietta
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- St. Anthony Hospital - Lakewood
Connecticut
- Hartford Health Care - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2030-10 |
| Phase | NA |
What the registry record for NCT03947619 still lists
NCT03947619 is an interventional study that assigns participants to a tested intervention. The registered 527 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 1 condition, with ST Elevation (STEMI) Myocardial Infarction of Anterior Wall appearing as the primary indexed condition, and to 1 intervention - of which Impella CP® placement prior to reperfusion with Primary PCI is the first listed.
NCT03947619 names 20 study sites across 11 states, led by Florida, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT03947619 about?
NCT03947619 is a clinical study titled "Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial". The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
What is the current status of trial NCT03947619?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 527 participants. The study started on 2019-12-12. Estimated completion is 2030-10.
What conditions does trial NCT03947619 study?
This clinical trial studies the following conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
What interventions are being tested in trial NCT03947619?
The interventions under investigation include: Impella CP® placement prior to reperfusion with Primary PCI (DEVICE).
Who is sponsoring clinical trial NCT03947619?
This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03947619 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03947619's enrollment target sits among peer trials
527 189th of 2000 higher than 1,812 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI